Polydrug use is common among people in drug treatment, with patterns varying by region.According to the limited data available on people in drug treatment, between 40 and 50 per cent of persons in drug-related treatment are polydrug users, with lower levels in Asia (22 per cent) and almost no…
Polydrug use poses significant risks and is more common among people with drug use disorders.No consensus definition of polydrug use currently exists but it can be generally understood as taking two or more drugs together or in sequence (intentionally or unintentionally), with both forms increasing…
The limited data available suggest that most overdose deaths involve multiple substances.Toxicological findings from 22 countries show that a median of 67 per cent of overdose deaths involve more than one substance.In 17 countries with available data, opioids and sedatives/tranquilizers are most…
Cannabis, ATS and opioids account for the highest numbers of people in drug-related treatment globally, with variation between regions and countries.In most reporting countries, cannabis or opioids are the most common primary drug among those in treatment. However, in the Caribbean, South America…
The use of cannabis and stimulant drugs continues to increaseGlobally, the use of cannabis and stimulant drugs such as amphetamines, cocaine and "ecstasy" increased in 2024, while the use of opioids remained largely stable.
Progress on strengthening the prevention and treatment of substance abuse – as formulated in SDG target 3.5 – remains limited.Coverage of treatment interventions for substance use disorders remains low globally, with new estimates for this indicator suggesting that, at the minimum, 8.2 per cent of…
Socio-economic profiles of people in drug-related treatment vary between regions, although this likely also partly reflects broader regional socio-economic differences.Based on data from 56 countries, employment status varies by region and subregion: in Asia, people in treatment are more likely to…
Stimulant drug use varies across countries and regionsAmphetamines are the most commonly used stimulant drug globally, followed by cocaine and "ecstasy"-type substances. Men show higher use across all stimulant drugs, though the ratio of men to women is lower for "ecstasy"-type substances.Cocaine…
Synthetic drug markets vary widely, with different substances dominating across countries and regionsThe most commonly used synthetic drugs differ by region: non-medical use of tramadol dominates West and Central Africa and methamphetamine is most prevalent in East and South-East Asia.New…
Fentanyls continue to account for the largest share of harm from the non-medical use of NPS synthetic opioids, in particular in North America, but the arrival on the market of nitazenes and orphines , which are often more potent than fentanyls, has led to a number of acute emergencies and fatal…
Limited data suggest stable or declining NPS use among young people, with some exceptions.Time-series data on NPS use among young people are scarce and largely limited to high-income countries.Where data are available, the use of NPS is generally stable or declining, as corroborated by recent…
Globally, the use of synthetic NPS continues to be lower than most internationally controlled drugs.Based on the available data – mainly from high-income countries – the use of synthetic NPS is generally lower than the use of drugs under international control. By contrast, the scarce data on plant-…
